Hemopexin Therapy Improves Cardiovascular Function by Preventing Heme-Induced Endothelial Toxicity in Mouse Models of Hemolytic Diseases | Zendy

Francesca Vinchi | Zendy; Lucia De Franceschi | Zendy; Alessandra Ghigo | Zendy; Tim M. Townes | Zendy; James J. Cimino | Zendy; Lorenzo Silengo | Zendy; Emilio Hirsch | Zendy; Fiorella Altruda | Zendy; Emanuela Tolosano | Zendy

Open Access

Hemopexin Therapy Improves Cardiovascular Function by Preventing Heme-Induced Endothelial Toxicity in Mouse Models of Hemolytic Diseases

Author(s) -

Francesca Vinchi,

Lucia De Franceschi,

Alessandra Ghigo,

Tim M. Townes,

James J. Cimino,

Lorenzo Silengo,

Emilio Hirsch,

Fiorella Altruda,

Emanuela Tolosano

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.130179

Subject(s) - hemopexin , heme , nitric oxide , heme oxygenase , reactive oxygen species , endothelial dysfunction , medicine , biochemistry , oxidative stress , pharmacology , chemistry , enzyme

Hemolytic diseases are characterized by enhanced intravascular hemolysis resulting in heme-catalyzed reactive oxygen species generation, which leads to endothelial dysfunction and oxidative damage. Hemopexin (Hx) is a plasma heme scavenger able to prevent endothelial damage and tissue congestion in a model of heme overload. Here, we tested whether Hx could be used as a therapeutic tool to counteract heme toxic effects on the cardiovascular system in hemolytic diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research